Browse Studies — Arctuva

Phase 3

Randomized, Multicenter, Vehicle-Controlled, Double-Masked Phase 3 Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with …

Non-Arteritic Anterior Ischemic Optic Neuropathy

Estimated

~$10 – $7,500

Dompé Farmaceutici S.p.ANCT07453888

Observational

New Non-invasive Modalities for Assessing Retinal Structure and Function:Preliminary Investigation

This study investigates a new technology to assess the structure and function inside the eye. Retinal imaging of subjects with inner and outer retinal defects …

Ischemic Optic NeuropathyBranch Retinal Artery OcclusionHemianopia+2 more

Estimated

~$10 – $7,500

Randy KardonNCT03475173

Observational

Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Retinal DiseaseAge-Related Macular DegenerationRetinitis Pigmentosa+15 more

Estimated

~$10 – $7,500

MD Stem CellsNCT03011541

Phase 1

A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]

The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open …

Open Angle Glaucoma (OAG)NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

Estimated

~$10 – $8,750

Life Biosciences Inc.NCT07290244